Efficacy of JAK1/2 inhibitors in AGS genes-related interferonopathies: A multicenter retrospective observational study with treated vs untreated comparison
Authors:
- 19 March 2026
- journal article
- research article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 148 (2) , 109907
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute
- IRCCS Fondazione Stella Maris
This publication has 44 references indexed in Scilit:
- Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety DatabaseDrug Safety, 2025
- Short-term efficacy of tofacitinib, a JAK inhibitor, in IFIH1-related Aicardi-Goutières syndromeEuropean Journal of Medical Genetics, 2025
- Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières SyndromeJournal of Clinical Immunology, 2024
- Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutières syndromeJournal of Neurology, 2023
- Treatment response to Janus kinase inhibitor in a child affected by Aicardi‐Goutières syndromeClinical Case Reports, 2023
- JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach StudyJournal of Clinical Immunology, 2023
- Autosomal dominant ADAR c.3019G>A (p.(G1007R)) variant is an important mimic of hereditary spastic paraplegia and cerebral palsyBrain and Development, 2022
- Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I InterferonopathyArthritis & Rheumatology, 2019
- Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1American Journal of Medical Genetics Part A, 2015
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseCurrent Opinion in Pharmacology, 2012